Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme, and its R&D pipeline includes early-stage antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile
, methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae
(DRSP). Ibezapolstat is currently enrolling in a Phase 2b clinical trial for the treatment of C. difficile
Infection. Our ACX-375C program for other Gram-positive, systemic infections is in preclinical lead optimization stage.